Biology

Evotec Expands its iPSC-Based Cell Therapy Platform EVOcells Through Licensing Agreement with panCELLa

Thursday, April 2, 2020 - 7:00am

With a growing portfolio of iPSC-based cell therapy projects at Evotec, access to research as well as GMP-grade iPSC lines modified with one or both of the panCELLa technologies significantly accelerates Evotec's cell therapy discovery and development efforts.

Key Points: 
  • With a growing portfolio of iPSC-based cell therapy projects at Evotec, access to research as well as GMP-grade iPSC lines modified with one or both of the panCELLa technologies significantly accelerates Evotec's cell therapy discovery and development efforts.
  • Modified iPSC lines will be available for the development of cell therapy approaches across a broad range of indications by Evotec and potential partners.
  • Integrating panCELLa's technology and cell lines into our ongoing proprietary research and development effortsstrengthens Evotec's position in cell therapy.
  • In addition to small molecules and biologics, cell therapy will become yet another major pillar of Evotec's multimodality discovery and development platform."

Dr. Roeland Nusse: Gairdner Award Recipient and Bio-Techne Board of Directors Member

Wednesday, April 1, 2020 - 9:01pm

MINNEAPOLIS, April 1, 2020 /PRNewswire/ --Bio-Techne Corporation (NASDAQ:TECH) today announced a member of its board of directors, Dr. Roeland Nusse, has become one of the 2020 Canada Gairdner International Award recipients.

Key Points: 
  • MINNEAPOLIS, April 1, 2020 /PRNewswire/ --Bio-Techne Corporation (NASDAQ:TECH) today announced a member of its board of directors, Dr. Roeland Nusse, has become one of the 2020 Canada Gairdner International Award recipients.
  • Annually, seven awards are given: five Canada Gairdner International Awards for biomedical research, one John Dirks Canada Gairdner Global Health Award, specifically for impact on global health issues, and one Canada Gairdner Wightman Award, reserved for a Canadian.
  • Chuck Kummeth, President and CEO of Bio-Techne stated: "We are honored to have Dr. Nusse on our board of directors.
  • Dr. Nusse joins an impressive list of past recipients of the Gairdner Award, including Drs.

Concert Genetics Presents Real-World Data on Utilization of NGS-Based Diagnostic Tests in NCCN 2020 Abstract

Wednesday, April 1, 2020 - 7:08pm

NASHVILLE, Tenn., April 1, 2020 /PRNewswire/ --Concert Genetics, a technology company dedicated to advancing precision medicine, today announced the publication ofreal-world data on utilization and coding variability in medical claims for Next-Generation Sequencing (NGS)-based diagnostic tests.

Key Points: 
  • NASHVILLE, Tenn., April 1, 2020 /PRNewswire/ --Concert Genetics, a technology company dedicated to advancing precision medicine, today announced the publication ofreal-world data on utilization and coding variability in medical claims for Next-Generation Sequencing (NGS)-based diagnostic tests.
  • "The breathtaking speed of innovation in precision medicine is outpacing the healthcare system's ability to adapt," said Rob Metcalf, CEO of Concert Genetics.
  • "As a result, the real-world data for observational research is often unavailable, too sparse, or insufficiently granular for evidence development.
  • Concert Genetics is a software and managed services company that advances precision medicine by providing thedigital infrastructure for reliable and efficient management of genetic testing.

Single Cell Sequencing Industry, Forecast to 2029: Expected to Grow at a Significant CAGR of 15.24%

Wednesday, April 1, 2020 - 2:45pm

DUBLIN, April 1, 2020 /PRNewswire/ -- The "Global Single Cell Sequencing Market: Focus on Products, Applications, Technologies, End Users, Country Data (17 Countries), and Competitive Landscape - Analysis and Forecast, 2018-2029" report has been added to ResearchAndMarkets.com's offering

Key Points: 
  • DUBLIN, April 1, 2020 /PRNewswire/ -- The "Global Single Cell Sequencing Market: Focus on Products, Applications, Technologies, End Users, Country Data (17 Countries), and Competitive Landscape - Analysis and Forecast, 2018-2029" report has been added to ResearchAndMarkets.com's offering
    The single cell sequencing industry analysis projects the market to grow at a significant CAGR of 15.24% during the forecast period, 2019-2029.
  • What are the major market drivers, challenges, and opportunities in the global single cell sequencing market?
  • What are the underlying structures resulting in the emerging trends within the global single cell sequencing market?
  • Who are the key manufacturers the global single cell sequencing market, and what are their contributions?

Antech Names Lonnie Shoff as its New President

Wednesday, April 1, 2020 - 2:00pm

Under Ms. Shoff's leadership, Antech will accelerate its development and commercialization of innovative diagnostic tests, predictive diagnostic tools, imaging technologies and education and support services.

Key Points: 
  • Under Ms. Shoff's leadership, Antech will accelerate its development and commercialization of innovative diagnostic tests, predictive diagnostic tools, imaging technologies and education and support services.
  • "I am excited to lead the next chapter of Antech's 30-year history," said Lonnie Shoff, President of Antech.
  • Finally, Ms. Shoff ended a 21-year tenure at Roche Diagnostics as Senior Vice President and General Manager of Molecular Diagnostics and Applied Science.
  • Ms. Shoff will assume her duties at Antech on April 15, 2020, reporting directly to Alejandro Bernal, President for Mars Veterinary Health International and Diagnostics.

Point of Care Molecular Diagnostics Market Expected to Reach $2.39 Billion by 2027 with a CAGR of 13.2% - ResearchAndMarkets.com

Wednesday, April 1, 2020 - 3:53pm

The point of care (POC) molecular diagnostics market is expected to grow at a CAGR of 13.2% from 2019 to 2027 to reach $2.39 billion by 2027.

Key Points: 
  • The point of care (POC) molecular diagnostics market is expected to grow at a CAGR of 13.2% from 2019 to 2027 to reach $2.39 billion by 2027.
  • The growth in the POC molecular diagnostics market is mainly attributed to the rising prevalence of chronic diseases, development of CLIA-waived POC molecular diagnostic tests, venture capital funding for the development of POC molecular diagnostic products, growing demand for POC molecular diagnostics, and need for rapid decision making in emergency care departments.
  • Based on the POC molecular diagnostic products, the kits & assays segment accounted for the largest share of the overall POC molecular diagnostics market in 2019.
  • Moreover, growing number of physicians adopting POC technologies and increasing focus of key companies on offering disease-specific POC molecular diagnostics drives the growth of the POC molecular diagnostics market for clinics and diagnostic laboratory segment.

Unchained Labs jumps into gene therapy and vaccines with new AAV stability application!

Wednesday, April 1, 2020 - 1:00pm

Uncle is already the gold standard for measuring protein stability and, with this new application, jumps in to support researchers in pursuit of novel gene therapies and better vaccines.

Key Points: 
  • Uncle is already the gold standard for measuring protein stability and, with this new application, jumps in to support researchers in pursuit of novel gene therapies and better vaccines.
  • Many gene therapies, immunotherapies and vaccines being developed use adeno-associated viruses or AAVs.
  • A stable AAV stays intact until it finds its target and won't aggregate-or worse, leak potentially toxic DNA into the body.
  • "With this new application, Uncle lends a helping hand to researchers working on life-changing gene therapies and vaccines," said Taegen Clary, VP of Marketing at Unchained Labs.

BioPorto and SDU in collaboration to fast track development of test to detect COVID-19 in less than 10 minutes

Wednesday, April 1, 2020 - 1:17pm

BioPorto Diagnostics A/S and University of Southern Denmark (SDU) develops COVID-19 test for early detection of infected patients to improve patient outcome and epidemic control.

Key Points: 
  • BioPorto Diagnostics A/S and University of Southern Denmark (SDU) develops COVID-19 test for early detection of infected patients to improve patient outcome and epidemic control.
  • Furthermore, serological tests may risk not identifying patients in the early phase of the disease, and therefore still relies on laboratory analysis for confirmation.
  • The rapid diagnosis means that people can go to work or travel by plane shortly after being tested.
  • BioPorto Diagnostics and University of Southern Denmark (SDU) have more than 20 years of successful partnership, developing nearly a hundred unique antibodies commercially available for research globally.

Unchained Labs jumps into gene therapy and vaccines with new AAV stability application!

Wednesday, April 1, 2020 - 1:00pm

Uncle is already the gold standard for measuring protein stability and, with this new application, jumps in to support researchers in pursuit of novel gene therapies and better vaccines.

Key Points: 
  • Uncle is already the gold standard for measuring protein stability and, with this new application, jumps in to support researchers in pursuit of novel gene therapies and better vaccines.
  • Many gene therapies, immunotherapies and vaccines being developed use adeno-associated viruses or AAVs.
  • A stable AAV stays intact until it finds its target and won't aggregate-or worse, leak potentially toxic DNA into the body.
  • "With this new application, Uncle lends a helping hand to researchers working on life-changing gene therapies and vaccines," said Taegen Clary, VP of Marketing at Unchained Labs.

Groundbreaking Technologies Fueling Novel Diagnostic & Precision Medicine Strategies, 2020 - ResearchAndMarkets.com

Wednesday, April 1, 2020 - 11:58am

The "Groundbreaking Technologies Fueling Novel Diagnostic and Precision Medicine Strategies" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Groundbreaking Technologies Fueling Novel Diagnostic and Precision Medicine Strategies" report has been added to ResearchAndMarkets.com's offering.
  • This edition of the Life Science, Health & Wellness TechVision Opportunity Engine (TOE) comprises groundbreaking advances across breast cancer screening, next generation sequencing, proteomics, and digital health platforms.
  • The TOE also provides insights across innovative immunotherapy and precision medicine strategies.
  • The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry.